<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070496</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0570</org_study_id>
    <nct_id>NCT03070496</nct_id>
  </id_info>
  <brief_title>Multicenter Cohort of STEMI Patients</brief_title>
  <acronym>HIBISCUS-STEMI</acronym>
  <official_title>CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemic heart disease is the leading cause of mortality with 7.2 million of death in&#xD;
      industrialized countries (WHO data). Myocardial infarction corresponding to acute occlusion&#xD;
      of a coronary artery is the most brutal form and the more severe ischemic myocardial disease.&#xD;
      Every year in France, about 60,000 Myocardial infarctions hospitalized, 30,000 are diagnosed&#xD;
      remotely and 30,000 are revealed by an inaugural sudden death. Although mortality from&#xD;
      myocardial decreased by 30% over the past decade, the prognosis is pejorative and difficult&#xD;
      to assess precisely. The management of the patient depends on these factors, and justifies an&#xD;
      active search on these topics, including the mechanisms of the deleterious ventricular&#xD;
      remodeling, myocardial inflammation, reperfusion injury which determines in particular the&#xD;
      evolution to heart failure. Cohorts of patients with myocardial infarction are rare but can&#xD;
      be very valuable by their clinical, laboratory and imaging well documented. They are the&#xD;
      source of new hypotheses for research or interventions as well as the quality of care&#xD;
      assessment tool.&#xD;
&#xD;
      The main objective of this project is to identify new markers: biological and imaging,&#xD;
      treatment response and prognosis after acute myocardial infarction.&#xD;
&#xD;
      Secondary objectives of the HIBISCUS-STEMI cohort to establish a clinical database, completed&#xD;
      by biological samples and by imaging data that can be used in the following areas:&#xD;
&#xD;
        -  Descriptive epidemiology of myocardial infarction and myocardial reperfusion&#xD;
&#xD;
        -  Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of&#xD;
           treatment in real life, costs&#xD;
&#xD;
        -  Assessment of the long-term effect of the treatment on the occurrence of heart failure&#xD;
           and sudden death&#xD;
&#xD;
        -  Quality of life and personal consequences, family, professional and social myocardial&#xD;
           infarction&#xD;
&#xD;
        -  Research of new diagnostic and prognostic biomarkers&#xD;
&#xD;
        -  Research projects (e.g. risk of developing kidney failure or stroke in patients with&#xD;
           myocardial infarction compared to the general population).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Anticipated">December 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart failure stage</measure>
    <time_frame>Up to 3 years after myocardial infarction</time_frame>
    <description>Heart failure stage will be assessed thanks to the New York Heart Association (NYHA) classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size</measure>
    <time_frame>1 month after myocardial infarction</time_frame>
    <description>Infarct size will be measured on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes rate</measure>
    <time_frame>H0 (admission in coronary angiography room)</time_frame>
    <description>Cardiac enzymes rate will be analysed in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes rate</measure>
    <time_frame>H4 (4 hours after reperfusion)</time_frame>
    <description>Cardiac enzymes rate will be analysed in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes rate</measure>
    <time_frame>H24 (24 hours after reperfusion)</time_frame>
    <description>Cardiac enzymes rate will be analysed in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes rate</measure>
    <time_frame>H48 (48 hours after reperfusion)</time_frame>
    <description>Cardiac enzymes rate will be analysed in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes rate</measure>
    <time_frame>1 month after myocardial infarction</time_frame>
    <description>Cardiac enzymes rate will be analysed in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes rate</measure>
    <time_frame>3 months after myocardial infarction</time_frame>
    <description>Cardiac enzymes rate will be analysed in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes rate</measure>
    <time_frame>6 months after myocardial infarction</time_frame>
    <description>Cardiac enzymes rate will be analysed in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes rate</measure>
    <time_frame>12 month after myocardial infarction</time_frame>
    <description>Cardiac enzymes rate will be analysed in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D score</measure>
    <time_frame>12 month after myocardial infarction</time_frame>
    <description>Patients' quality of life will be evaluated thanks to the EQ-5D questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">281</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>STEMI cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients recruited in the cohort will have 4 additional interventions compared to the usual follow-up :&#xD;
an additional blood sampling at 6 months&#xD;
an additional electrocardiogram (ECG) at 6 months&#xD;
Magnetic Resonance Imaging (MRI)&#xD;
Quality of life questionnaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers</description>
    <arm_group_label>STEMI cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ECG</intervention_name>
    <description>ECG will be performed at 6 months after myocardial infarction</description>
    <arm_group_label>STEMI cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.</description>
    <arm_group_label>STEMI cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life questionnaire</intervention_name>
    <description>Patients will pass a quality of life questionnaire at 12 months after myocardial infarction</description>
    <arm_group_label>STEMI cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Diagnosis of STEMI defined by ST segment elevation â‰¥ 0.2 mV in 2 contiguous leads on a&#xD;
             12-lead ECG.&#xD;
&#xD;
          -  Primary Percutaneous coronary intervention (PCI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of STEMI not confirmed by angiography&#xD;
&#xD;
          -  Refusal to participate in the study or to sign the consent&#xD;
&#xD;
          -  Impossibility to give information to the subject about the study&#xD;
&#xD;
          -  Lack of medical social coverage&#xD;
&#xD;
          -  Obvious contraindication to magnetic resonance imaging (claustrophobia, pacemaker,&#xD;
             defibrillator, renal insufficiency, known allergy to a contrast agent)&#xD;
&#xD;
          -  Deprivation of civil rights&#xD;
&#xD;
          -  participating to another interventional study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel OVIZE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel OVIZE, MD, PhD</last_name>
    <phone>+33 472 357 170</phone>
    <email>ghe.ciclyon@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvonne VARILLON, CRA</last_name>
    <phone>+33 472 35 69 64</phone>
    <email>yvonne.varillona@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HÃ´pital Cardiovasculaire Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel OVIZE, MD, PhD</last_name>
      <phone>+33 472 357 170</phone>
      <email>ghe.ciclyon@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Lakhdar BENYAHYA, CRA</last_name>
      <phone>+33 472 356 972</phone>
      <email>lakhdar.benyahya@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Michel OVIZE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MOREL, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier MOREL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis ANGOULVANT, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Denis ANGOULVANT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>bio-collection</keyword>
  <keyword>Imaging markers</keyword>
  <keyword>biomarkers</keyword>
  <keyword>STEMI</keyword>
  <keyword>clinical outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

